reports
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, ...
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeu...
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at...
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneering Phase 3 clinical study titled SMART 2.0. The proposed trial would investigate the potential of oral (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition, to si...
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, ...
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations. This new...
Atossa Therapeutics Announces Full Year 2024 Financial Results and Pro...
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company develop...
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financ...
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-ye...
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer...
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes that pursuing a metastatic indication may offer a more efficient regulatory pathway to deliver (Z)-endoxifen to women in ...
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and ...
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers fo...
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,...
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board’s (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the “’334 patent”). Atossa is disappointed with the PTAB’s decision finding all challenged claims i...
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Ac...
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows: To our valued shareholders, As we reflect on 2024, I am proud to share the remark...
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlight...
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, commends the U.S. Surgeon General for issuing a crucial Advisory that describes the scientific evidence for the causal link between alcohol consumption and increased cancer risk, particularly breast cancer in women. The Surgeon General’s Advisory reveals that alcohol consu...
Atossa Therapeutics to Present Poster Describing the Discovery of Mole...
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer Treatments SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in...
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxi...
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density 1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium SEATTLE, Dec. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced full results from its Phase 2 KARISMA-Endoxifen trial conducted at the Karolinska...
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data f...
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024). EV...
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer...
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research Novel Compounds Demonstrate Promising Anti-Tumor Activity in Estrogen Receptor-Positive (ERα+) Breast Cancer, Including Endocrine-Resistant Tumors SEATTLE, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the presentation of ...
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special...
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that a poster detailing the anti-cancer activity of (Z)-endoxifen-related compounds in estrogen receptor alpha-positive (ERα+) breast cancer will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research in Toronto from December 9-11, 2024. Atossa is ...
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxife...
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen’s ability to significantly reduce mammographic breast density to be featured at conference SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that...
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and...
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical tria...
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice Presiden...
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa’s Mission in Developing Innovative Breast Cancer Therapies SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global c...
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: (Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today released positive topline data from the KARISMA-Endoxifen Phase 2 study of (Z)-endoxifen in premenopausal women with mammographic breast density (MBD). The study, whic...
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrat...
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer (Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial Low dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 and FTV Biomarkers SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today released a preliminary analysis from a ph...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.